Class effect of pharmacotherapy in bipolar disorder: Fact or misbelief?

Annals of General Psychiatry

Volumn 10, Issue , 2011, Pages

  Fountoulakis, Konstantinos N ^a   Gonda, Xenia ^b   Vieta, Eduard ^c   Rihmer, Zoltan ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ASENAPINE; CARBAMAZEPINE; CHLORPROMAZINE; CLOZAPINE; FLUOXETINE; GABAPENTIN; HALOPERIDOL; LAMOTRIGINE; LICARBAZEPINE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PAROXETINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; TOPIRAMATE; VALPROIC ACID; VENLAFAXINE; ZIPRASIDONE;

BIPOLAR DEPRESSION; BIPOLAR DISORDER; DRUG EFFICACY; DRUG INDICATION; HUMAN; MAINTENANCE THERAPY; MANIA; MONOTHERAPY; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME;

EID: 79953117256     PISSN: None     EISSN: 1744859X     Source Type: Journal    
DOI: 10.1186/1744-859X-10-8     Document Type: Review

References (144)

1. Ng B, Camacho A, Lara DR, Brunstein MG, Pinto OC, Akiskal HS. A case series on the hypothesized connection between dementia and bipolar spectrum disorders: bipolar type VI?. J Affect Disord 2008, 107:307-315. 10.1016/j.jad.2007.08.018, 17889374.
2. Akiskal HS. The prevalent clinical spectrum of bipolar disorders: beyond DSM-IV. J Clin Psychopharmacol 1996, 16(Suppl 1):4S-14S. 10.1097/00004714-199604001-00002, 8707999.
3. Akiskal HS, Pinto O. The evolving bipolar spectrum. Prototypes I, II, III, and IV. Psychiatr Clin North Am 1999, 22:517-534. vii, 10.1016/S0193-953X(05)70093-9, 10550853.
4. Angst J. The emerging epidemiology of hypomania and bipolar II disorder. J Affect Disord 1998, 50:143-151. 10.1016/S0165-0327(98)00142-6, 9858074.
5. Judd LL, Akiskal HS. The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases. J Affect Disord 2003, 73:123-131. 10.1016/S0165-0327(02)00332-4, 12507745.
6. Acorn S. Mental and physical health of homeless persons who use emergency shelters in Vancouver. Hosp Community Psychiatry 1993, 44:854-857.
7. World Health Organization The World Health Report 2003 - Shaping The Future 2003, Geneva, Switzerland: WHO, World Health Organization.
8. Fountoulakis KN, Grunze H, Panagiotidis P, Kaprinis G. Treatment of bipolar depression: an update. J Affect Disord 2008, 109:21-34. 10.1016/j.jad.2007.10.016, 18037498.
9. Fountoulakis KN, Magiria S, Siamouli M, Panagiotidis P, Nimatoudis I, Iacovides A, Kaprinis GS. A seven-year follow-up of an extremely refractory bipolar I patient. CNS Spectrum 2007, 12:733-734.
10. Fountoulakis KN, Vieta E, Sanchez-Moreno J, Kaprinis SG, Goikolea JM, Kaprinis GS. Treatment guidelines for bipolar disorder: a critical review. J Affect Disord 2005, 86:1-10. 10.1016/j.jad.2005.01.004, 15820265.
11. Fountoulakis KN, Vieta E, Siamouli M, Valenti M, Magiria S, Oral T, Fresno D, Giannakopoulos P, Kaprinis GS. Treatment of bipolar disorder: a complex treatment for a multi-faceted disorder. Ann Gen Psychiatry 2007, 6:27. 10.1186/1744-859X-6-27, 2089060, 17925035.
12. Nivoli AM, Colom F, Murru A, Pacchiarotti I, Castro-Loli P, Gonzalez-Pinto A, Fountoulakis KN, Vieta E. New treatment guidelines for acute bipolar depression: a systematic review. J Affect Disord 2011, 129:14-26. 10.1016/j.jad.2010.05.018, 20538341.
13. Fountoulakis KN. An update of evidence-based treatment of bipolar depression: where do we stand?. Curr Opin Psychiatry 2010, 23:19-24. 10.1097/YCO.0b013e328333e132, 19901836.
14. Fountoulakis KN, Vieta E. Efficacy and safety of aripiprazole in the treatment of bipolar disorder: a systematic review. Ann Gen Psychiatry 2009, 8:16. 10.1186/1744-859X-8-16, 2724509, 19635147.
15. Fountoulakis KN, Gonda X, Vieta E, Schmidt F. Treatment of psychotic symptoms in bipolar disorder with aripiprazole monotherapy: a meta-analysis. Ann Gen Psychiatry 2009, 8:27. 10.1186/1744-859X-8-27, 2812439, 20043829.
16. Fountoulakis KN, Vieta E. Treatment of bipolar disorder: a systematic review of available data and clinical perspectives. Int J Neuropsychopharmacol 2008, 11:999-1029.
17. Pope HG, McElroy SL, Keck PE, Hudson JI. Valproate in the treatment of acute mania. A placebo-controlled study. Arch Gen Psychiatry 1991, 48:62-68.
18. Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PG, Petty F, Dilsaver SC, Davis JM, Rush AJ, Small JG, Garza-Treviño ES, Risch SC, Goodnick PJ, Morris DD, Shu V, Johnson P, Blake M, Javors M, Ereshefsky L, McLeod T, Shoaib A, Johnson M, Kimmel S, Wesley A, Qualtiere R, Trivedi C, Javaid J, Peterson J, Lambert M, et al. Depakote Mania Study Group Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA 1994, 271:918-924. 10.1001/jama.271.12.918, 8120960, Depakote Mania Study Group.
19. Bowden CL, Swann AC, Calabrese JR, Rubenfaer LM, Wozniak PJ, Collins MA, Abi-Saab W, Saltarelli M. A randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania. J Clin Psychiatry 2006, 67:1501-1510. 10.4088/JCP.v67n1003, 17107240.
20. Tohen M, Vieta E, Goodwin GM, Sun B, Amsterdam JD, Banov M, Shekhar A, Aaronson ST, Bardenstein L, Grecu-Gabos I, Tochilov V, Prelipceanu D, Oliff HS, Kryzhanovskaya L, Bowden C. Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind study. J Clin Psychiatry 2008, 69:1776-1789. 10.4088/JCP.v69n1113, 19014751.
21. Emrich HM, von Zerssen D, Kissling W, Moller HJ, Windorfer A. Effect of sodium valproate on mania. The GABA-hypothesis of affective disorders. Archiv fur Psychiatrie und Nervenkrankheiten 1980, 229:1-16. 10.1007/BF00343800, 6778456.
22. Emrich HM, von Zerssen D, Kissling W, Moller HJ. Therapeutic effect of valproate in mania. Am J Psychiatry 1981, 138:256.
23. Davis LL, Bartolucci A, Petty F. Divalproex in the treatment of bipolar depression: a placebo-controlled study. J Affect Disord 2005, 85:259-266. 10.1016/j.jad.2004.09.009, 15780695.
24. Ghaemi SN, Gilmer WS, Goldberg JF, Zablotsky B, Kemp DE, Kelley ME, Bauer AD, Fleck J, Filkowski MM, Stan VA, Dunn RT. Divalproex in the treatment of acute bipolar depression: a preliminary double-blind, randomized, placebo-controlled pilot study. J Clin Psychiatry 2007, 68:1840-1844. 10.4088/JCP.v68n1203, 18162014.
25. Bond DJ, Lam RW, Yatham LN. Divalproex sodium versus placebo in the treatment of acute bipolar depression: a systematic review and meta-analysis. J Affect Disord 2010, 124:228-234. 10.1016/j.jad.2009.11.008, 20044142.
26. Smith LA, Cornelius VR, Azorin JM, Perugi G, Vieta E, Young AH, Bowden CL. Valproate for the treatment of acute bipolar depression: Systematic review and meta-analysis. J Affect Disord 2010, 122:1-9. 10.1016/j.jad.2009.10.033, 19926140.
27. Bowden CL, Calabrese JR, McElroy SL, Gyulai L, Wassef A, Petty F, Pope HG, Chou JC, Keck PE, Rhodes LJ, Swann AC, Hirschfeld RM, Wozniak PJ. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 2000, 57:481-489. 10.1001/archpsyc.57.5.481, 10807488.
28. Ballenger JC, Post RM. Carbamazepine in manic-depressive illness: a new treatment. Am J Psychiatry 1980, 137:782-790.
29. Weisler RH, Kalali AH, Ketter TA. A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry 2004, 65:478-484. 10.4088/JCP.v65n0405, 15119909.
30. Weisler RH, Hirschfeld R, Cutler AJ, Gazda T, Ketter TA, Keck PE, Swann A, Kalali A. Extended-release carbamazepine capsules as monotherapy in bipolar disorder: pooled results from two randomised, double-blind, placebo-controlled trials. CNS Drugs 2006, 20:219-231. 10.2165/00023210-200620030-00004, 16529527.
31. Weisler RH, Keck PE, Swann AC, Cutler AJ, Ketter TA, Kalali AH. Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2005, 66:323-330. 10.4088/JCP.v66n0308, 15766298.
32. Okuma T, Inanaga K, Otsuki S, Sarai K, Takahashi R, Hazama H, Mori A, Watanabe S. A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness. Psychopharmacology (Berl) 1981, 73:95-96. 10.1007/BF00431111, 6785799.
33. Goldsmith DR, Wagstaff AJ, Ibbotson T, Perry CM. Lamotrigine: a review of its use in bipolar disorder. Drugs 2003, 63:2029-2050. 10.2165/00003495-200363190-00009, 12962521.
34. Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 1999, 60:79-88. 10.4088/JCP.v60n0203, 10084633.
35. van der Loos ML, Mulder PG, Hartong EG, Blom MB, Vergouwen AC, de Keyzer HJ, Notten PJ, Luteijn ML, Timmermans MA, Vieta E, Nolen WA, . LamLit Study Group Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry 2009, 70:223-231. 10.4088/JCP.08m04152, 19200421, LamLit Study Group.
36. Bowden CL, Calabrese JR, Sachs G, Yatham LN, Asghar SA, Hompland M, Montgomery P, Earl N, Smoot TM, DeVeaugh-Geiss J. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003, 60:392-400. 10.1001/archpsyc.60.4.392, 12695317.
37. Calabrese JR, Bowden CL, Sachs G, Yatham LN, Behnke K, Mehtonen OP, Montgomery P, Ascher J, Paska W, Earl N, DeVeaugh-Geiss J, . Lamictal 605 Study Group A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003, 64:1013-1024. 10.4088/JCP.v64n0906, 14628976, Lamictal 605 Study Group.
38. Calabrese JR, Goldberg JF, Ketter TA, Suppes T, Frye M, White R, DeVeaugh-Geiss A, Thompson TR. Recurrence in bipolar I disorder: a post hoc analysis excluding relapses in two double-blind maintenance studies. Biol Psychiatry 2006, 59:1061-1064. 10.1016/j.biopsych.2006.02.034, 16769295.
39. Calabrese JR, Vieta E, Shelton MD. Latest maintenance data on lamotrigine in bipolar disorder. Eur Neuropsychopharmacol 2003, 13(Suppl 2):S57-66. 10.1016/S0924-977X(03)00079-8, 12957721.
40. Goodwin GM, Bowden CL, Calabrese JR, Grunze H, Kasper S, White R, Greene P, Leadbetter R. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 2004, 65:432-441. 10.4088/JCP.v65n0321, 15096085.
41. Frye MA, Ketter TA, Kimbrell TA, Dunn RT, Speer AM, Osuch EA, Luckenbaugh DA, Cora-Ocatelli G, Leverich GS, Post RM. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000, 20:607-614. 10.1097/00004714-200012000-00004, 11106131.
42. Kushner SF, Khan A, Lane R, Olson WH. Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials. Bipolar Disord 2006, 8:15-27. 10.1111/j.1399-5618.2006.00276.x, 16411977.
43. Klein DF. Importance of psychiatric diagnosis in prediction of clinical drug effects. Arch Gen Psychiatry 1967, 16:118-126.
44. Shopsin B, Gershon S, Thompson H, Collins P. Psychoactive drugs in mania. A controlled comparison of lithium carbonate, chlorpromazine, and haloperidol. Arch Gen Psychiatry 1975, 32:34-42.
45. McIntyre RS, Brecher M, Paulsson B, Huizar K, Mullen J. Quetiapine or haloperidol as monotherapy for bipolar mania - a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur Neuropsychopharmacol 2005, 15:573-585. 10.1016/j.euroneuro.2005.02.006, 16139175.
46. Smulevich AB, Khanna S, Eerdekens M, Karcher K, Kramer M, Grossman F. Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. Eur Neuropsychopharmacol 2005, 15:75-84. 10.1016/j.euroneuro.2004.06.003, 15572276.
47. Young A, Oren D, Lowy A, McQuade RD, Marcus RN, Carson W, Spiller N, Torbeyns A, Sanchez R. Aripiprazol monotherapy in acute mania: a 12-week, randomized, placebo and haloperidol- controlled study. Br J Psychiatry 2009, 194:40-48. 10.1192/bjp.bp.108.049965, 19118324.
48. Vieta E, Ramey T, Keller D, English P, Loebel A, Miceli J. Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study. J Psychopharmacol 2010, 4:547-558.
49. Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, Azorin JM, Vieta E, Hardy-Bayle MC, Lawson WB, Emsley RA, Zhang F, Baker RW, Risser RC, Namjoshi MA, Evans AR, Breier A. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry 2003, 60:1218-1226. 10.1001/archpsyc.60.12.1218, 14662554.
50. Zarate CA, Tohen M. Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients. Am J Psychiatry 2004, 161:169-171. 10.1176/appi.ajp.161.1.169, 14702269.
51. Tohen M, Sanger TM, McElroy SL, Tollefson GD, Chengappa KN, Daniel DG, Petty F, Centorrino F, Wang R, Grundy SL, Greaney MG, Jacobs TG, David SR, Toma V. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry 1999, 156:702-709.
52. Tohen M, Jacobs TG, Grundy SL, McElroy SL, Banov MC, Janicak PG, Sanger T, Risser R, Zhang F, Toma V, Francis J, Tollefson GD, Breier A. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. Arch Gen Psychiatry 2000, 57:841-849. 10.1001/archpsyc.57.9.841, 10986547.
53. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine in the treatment of acute mania in bipolar I disorder: A randomized, double-blind, placebo-controlled trial. J Affect Disord 2010, 122:27-38. 10.1016/j.jad.2009.12.028, 20096936.
54. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord 2009, 11:673-686. 10.1111/j.1399-5618.2009.00748.x, 19839993.
55. Meehan K, Zhang F, David S, Tohen M, Janicak P, Small J, Koch M, Rizk R, Walker D, Tran P, Breier A. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol 2001, 21:389-397. 10.1097/00004714-200108000-00006, 11476123.
56. Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, Mitchell PB, Centorrino F, Risser R, Baker RW, Evans AR, Beymer K, Dube S, Tollefson GD, Breier A. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003, 60:1079-1088. 10.1001/archpsyc.60.11.1079, 14609883.
57. Bech P. Meta-analysis of placebo-controlled trials with mirtazapine using the core items of the Hamilton Depression Scale as evidence of a pure antidepressive effect in the short-term treatment of major depression. Int J Neuropsychopharmacol 2001, 4:337-345. 10.1017/S1461145701002565, 11806859.
58. Lecrubier Y, Bech P. The Ham D(6) is more homogenous and as sensitive as the Ham D(17). Eur Psychiatry 2007, 22:252-255. 10.1016/j.eurpsy.2007.01.1218, 17344030.
59. Tohen M, Calabrese JR, Sachs GS, Banov MD, Detke HC, Risser R, Baker RW, Chou JC, Bowden CL. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 2006, 163:247-256. 10.1176/appi.ajp.163.2.247, 16449478.
60. Tohen M, Sutton VK, Calabrese JR, Sachs GS, Bowden CL. Maintenance of response following stabilization of mixed index episodes with olanzapine monotherapy in a randomized, double-blind, placebo-controlled study of bipolar 1 disorder. J Affect Disord 2009, 116:43-50. 10.1016/j.jad.2008.11.003, 19054570.
61. Brown E, Dunner DL, McElroy SL, Keck PE, Adams DH, Degenhardt E, Tohen M, Houston JP. Olanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar I depression. Int J Neuropsychopharmacol 2009, 12:773-782. 10.1017/S1461145708009735, 19079815.
62. Brown EB, McElroy SL, Keck PE, Deldar A, Adams DH, Tohen M, Williamson DJ. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry 2006, 67:1025-1033. 10.4088/JCP.v67n0703, 16889444.
63. Shi L, Namjoshi MA, Swindle R, Yu X, Risser R, Baker RW, Tohen M. Effects of olanzapine alone and olanzapine/fluoxetine combination on health-related quality of life in patients with bipolar depression: secondary analyses of a double-blind, placebo-controlled, randomized clinical trial. Clin Ther 2004, 26:125-134. 10.1016/S0149-2918(04)90013-6, 14996525.
64. Dube S, Tollefson GD, Thase ME, Briggs SD, Van Campen LE, Case M, Tohen M. Onset of antidepressant effect of olanzapine and olanzapine/fluoxetine combination in bipolar depression. Bipolar Disord 2007, 9:618-627. 10.1111/j.1399-5618.2007.00491.x, 17845277.
65. Bowden CL, Grunze H, Mullen J, Brecher M, Paulsson B, Jones M, Vagero M, Svensson K. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry 2005, 66:111-121. 10.4088/JCP.v66n0116, 15669897.
66. McElroy SL, Martens BE, Winstanley EL, Creech R, Malhotra S, Keck PE. Placebo-controlled study of quetiapine monotherapy in ambulatory bipolar spectrum disorder with moderate-to-severe hypomania or mild mania. J Affect Disord 2010, 124:157-163. 10.1016/j.jad.2009.11.014, 19963274.
67. Calabrese JR, Keck PE, Macfadden W, Minkwitz M, Ketter TA, Weisler RH, Cutler AJ, McCoy R, Wilson E, Mullen J. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005, 162:1351-1360. 10.1176/appi.ajp.162.7.1351, 15994719.
68. McElroy SL, Weisler RH, Chang W, Olausson B, Paulsson B, Brecher M, Agambaram V, Merideth C, Nordenhem A, Young AH. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry 2010, 71:163-174. 10.4088/JCP.08m04942gre, 20122366.
69. Young AH, McElroy SL, Bauer M, Philips N, Chang W, Olausson B, Paulsson B, Brecher M. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry 2010, 71:150-162. 10.4088/JCP.08m04995gre, 20122369.
70. Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A, Calabrese JR. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 2006, 26:600-609. 10.1097/01.jcp.0000248603.76231.b7, 17110817.
71. Suppes T, Datto C, Minkwitz M, Nordenhem A, Walker C, Darko D. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. J Affect Disord 2010, 121:106-115. 10.1016/j.jad.2009.10.007, 19903574.
72. Cookson J, Keck PE, Ketter TA, Macfadden W. Number needed to treat and time to response/remission for quetiapine monotherapy efficacy in acute bipolar depression: evidence from a large, randomized, placebo-controlled study. Int Clin Psychopharmacol 2007, 22:93-100. 10.1097/YIC.0b013e3280119dfb, 17293709.
73. Weisler RH, Calabrese JR, Thase ME, Arvekvist R, Stening G, Paulsson B, Suppes T. Efficacy of quetiapine monotherapy for the treatment of depressive episodes in bipolar I disorder: a post hoc analysis of combined results from 2 double-blind, randomized, placebo-controlled studies. J Clin Psychiatry 2008, 69:769-782. 10.4088/JCP.v69n0510, 18452345.
74. Endicott J, Rajagopalan K, Minkwitz M, Macfadden W. A randomized, double-blind, placebo-controlled study of quetiapine in the treatment of bipolar I and II depression: improvements in quality of life. Int Clin Psychopharmacol 2007, 22:29-37. 10.1097/01.yic.0000224797.74771.be, 17159457.
75. Suppes T, Hirschfeld RM, Vieta E, Raines S, Paulsson B. Quetiapine for the treatment of bipolar II depression: analysis of data from two randomized, double-blind, placebo-controlled studies. World J Biol Psychiatry 2008, 9:198-211. 10.1080/15622970701317265, 17853277.
76. Vieta E, Suppes T, Eggens I, Persson I, Paulsson B, Brecher M. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord 2008, 109:251-263. 10.1016/j.jad.2008.06.001, 18579216.
77. Suppes T, Vieta E, Liu S, Brecher M, Paulsson B. Maintenance treatment for patients with bipolar I disorder: results from a north american study of quetiapine in combination with lithium or divalproex (trial 127). Am J Psychiatry 2009, 166:476-488. 10.1176/appi.ajp.2008.08020189, 19289454.
78. Keck PE, Marcus R, Tourkodimitris S, Ali M, Liebeskind A, Saha A, Ingenito G. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003, 160:1651-1658. 10.1176/appi.ajp.160.9.1651, 12944341.
79. Sachs G, Sanchez R, Marcus R, Stock E, McQuade R, Carson W, Abou-Gharbia N, Impellizzeri C, Kaplita S, Rollin L, Iwamoto T, . Aripiprazole Study Group Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol 2006, 20:536-546. 10.1177/0269881106059693, 16401666, Aripiprazole Study Group.
80. Keck PE, Orsulak PJ, Cutler AJ, Sanchez R, Torbeyns A, Marcus RN, McQuade RD, Carson WH, . (CN138-135 Study Group) Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study. J Affect Disord 2009, 112:36-49. 10.1016/j.jad.2008.05.014, 18835043, (CN138-135 Study Group).
81. Garcia-Amador M, Pacchiarotti I, Valenti M, Sanchez RF, Goikolea JM, Vieta E. Role of aripiprazole in treating mood disorders. Exp Rev Neurotherapeutics 2006, 6:1777-1783.
82. Thase ME, Jonas A, Khan A, Bowden CL, Wu X, McQuade RD, Carson WH, Marcus RN, Owen R. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol 2008, 28:13-20. 10.1097/jcp.0b013e3181618eb4, 18204335.
83. Keck PE, Calabrese JR, McQuade RD, Carson WH, Carlson BX, Rollin LM, Marcus RN, Sanchez R. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 2006, 67:626-637. 10.4088/JCP.v67n0414, 16669728.
84. Keck PE, Calabrese JR, McIntyre RS, McQuade RD, Carson WH, Eudicone JM, Carlson BX, Marcus RN, Sanchez R. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry 2007, 68:1480-1491. 10.4088/JCP.v68n1003, 17960961.
85. Gopal S, Steffens DC, Kramer ML, Olsen MK. Symptomatic remission in patients with bipolar mania: results from a double-blind, placebo-controlled trial of risperidone monotherapy. J Clin Psychiatry 2005, 66:1016-1020. 10.4088/JCP.v66n0809, 16086617.
86. Hirschfeld RM, Keck PE, Kramer M, Karcher K, Canuso C, Eerdekens M, Grossman F. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry 2004, 161:1057-1065. 10.1176/appi.ajp.161.6.1057, 15169694.
87. Khanna S, Vieta E, Lyons B, Grossman F, Eerdekens M, Kramer M. Risperidone in the treatment of acute mania: double-blind, placebo-controlled study. Br J Psychiatry 2005, 187:229-234. 10.1192/bjp.187.3.229, 16135859.
88. Quiroz JA, Yatham LN, Palumbo JM, Karcher K, Kushner S, Kusumakar V. Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biol Psychiatry 2010, 68:156-162. 10.1016/j.biopsych.2010.01.015, 20227682.
89. Keck PE, Versiani M, Potkin S, West SA, Giller E, Ice K. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry 2003, 160:741-748. 10.1176/appi.ajp.160.4.741, 12668364.
90. Potkin SG, Keck PE, Segal S, Ice K, English P. Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. J Clin Psychopharmacol 2005, 25:301-310. 10.1097/01.jcp.0000169068.34322.70, 16012271.
91. Stahl S, Lombardo I, Loebel A, Mandel FS. Efficacy of ziprasidone in dysphoric mania: pooled analysis of two double-blind studies. J Affect Disord 2010, 122:39-45. 10.1016/j.jad.2009.06.023, 19616304.
92. Bowden CL, Vieta E, Ice KS, Schwartz JH, Wang PP, Versavel M. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. J Clin Psychiatry 2010, 71:130-137. 10.4088/JCP.09m05482yel, 20122373.
93. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Affect Disord 2010, 122:27-38. 10.1016/j.jad.2009.12.028, 20096936.
94. Vieta E, Nuamah IF, Lim P, Yuen EC, Palumbo JM, Hough DW, Berwaerts J. A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder. Bipolar Disord 2010, 12:230-243. 10.1111/j.1399-5618.2010.00815.x, 20565430.
95. Glen AI, Johnson AL, Shepherd M. Continuation therapy with lithium and amitriptyline in unipolar depressive illness: a randomized, double-blind, controlled trial. Psychol Med 1984, 14:37-50. 10.1017/S0033291700003068, 6143340.
96. Prien RF, Kupfer DJ, Mansky PA, Small JG, Tuason VB, Voss CB, Johnson WE. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination. Arch Gen Psychiatry 1984, 41:1096-1104.
97. Prien RF, Klett CJ, Caffey EM. Lithium carbonate and imipramine in prevention of affective episodes. A comparison in recurrent affective illness. Arch Gen Psychiatry 1973, 29:420-425.
98. Kane JM, Quitkin FM, Rifkin A, Ramos-Lorenzi JR, Nayak DD, Howard A. Lithium carbonate and imipramine in the prophylaxis of unipolar and bipolar II illness: a prospective, placebo-controlled comparison. Arch Gen Psychiatry 1982, 39:1065-1069.
99. Cohn JB, Collins G, Ashbrook E, Wernicke JF. A comparison of fluoxetine imipramine and placebo in patients with bipolar depressive disorder. Int Clin Psychopharmacol 1989, 4:313-322. 10.1097/00004850-198910000-00006, 2607128.
100. Amsterdam JD, Garcia-Espana F, Fawcett J, Quitkin FM, Reimherr FW, Rosenbaum JF, Schweizer E, Beasley C. Efficacy and safety of fluoxetine in treating bipolar II major depressive episode. J Clin Psychopharmacol 1998, 18:435-440. 10.1097/00004714-199812000-00003, 9864074.
101. Amsterdam JD, Shults J. Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar type I and type II major depression--lack of manic induction. J Affect Disord 2005, 87:121-130. 10.1016/j.jad.2005.02.018, 15923042.
102. Parker G, Tully L, Olley A, Hadzi-Pavlovic D. SSRIs as mood stabilizers for bipolar II disorder? A proof of concept study. J Affect Disord 2006, 92:205-214. 10.1016/j.jad.2006.01.024, 16516304.
103. McElroy SL, Weisler RH, Chang W, Olausson B, Paulsson B, Brecher M, Agambaram V, Merideth C, Nordenhem A, Young AH. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry 2010, 71:163-174. 10.4088/JCP.08m04942gre, 20122366.
104. Vieta E, Martinez-Aran A, Goikolea JM, Torrent C, Colom F, Benabarre A, Reinares M. A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J Clin Psychiatry 2002, 63:508-512. 10.4088/JCP.v63n0607, 12088162.
105. Rosa AR, Cruz N, Franco C, Haro JM, Bertsch J, Reed C, Aarre TF, Sanchez-Moreno J, Vieta E. Why do clinicians maintain antidepressants in some patients with acute mania? Hints from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM), a large naturalistic study. J Clin Psychiatry 2010, 71:1000-1006. 10.4088/JCP.09m05026gre, 20361912.
106. Amsterdam JD, Shults J. Fluoxetine monotherapy of bipolar type II and bipolar NOS major depression: a double-blind, placebo-substitution, continuation study. Int Clin Psychopharmacol 2005, 20:257-264. 10.1097/01.yic.0000171519.64080.c9, 16096516.
107. Garfinkel PE, Stancer HC, Persad E. A comparison of haloperidol, lithium carbonate and their combination in the treatment of mania. J Affect Disord 1980, 2:279-288. 10.1016/0165-0327(80)90029-4, 6450787.
108. Sachs GS, Grossman F, Ghaemi SN, Okamoto A, Bowden CL. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry 2002, 159:1146-1154. 10.1176/appi.ajp.159.7.1146, 12091192.
109. Chou JC, Czobor P, Charles O, Tuma I, Winsberg B, Allen MH, Trujillo M, Volavka J. Acute mania: haloperidol dose and augmentation with lithium or lorazepam. J Clin Psychopharmacol 1999, 19:500-505. 10.1097/00004714-199912000-00003, 10587284.
110. Lenox RH, Newhouse PA, Creelman WL, Whitaker TM. Adjunctive treatment of manic agitation with lorazepam versus haloperidol: a double-blind study. J Clin Psychiatry 1992, 53:47-52.
111. Small JG, Klapper MH, Marhenke JD, Milstein V, Woodham GC, Kellams JJ. Lithium combined with carbamazepine or haloperidol in the treatment of mania. Psychopharmacol Bull 1995, 31:265-272.
112. Klein E, Bental E, Lerer B, Belmaker RH. Carbamazepine and haloperidol v placebo and haloperidol in excited psychoses. A controlled study. Arch Gen Psychiatry 1984, 41:165-170.
113. Tohen M, Bowden CL, Smulevich AB, Bergstrom R, Quinlan T, Osuntokun O, Wang WV, Oliff HS, Martenyi F, Kryzhanovskaya LA, Greil W. Olanzapine plus carbamazepine v. carbamazepine alone in treating manic episodes. Br J Psychiatry 2008, 192:135-143. 10.1192/bjp.bp.107.041301, 18245032.
114. Yatham LN, Grossman F, Augustyns I, Vieta E, Ravindran A. Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial. Br J Psychiatry 2003, 182:141-147. 10.1192/bjp.182.2.141, 12562742.
115. Juruena MF, Ottoni GL, Machado-Vieira R, Carneiro RM, Weingarthner N, Marquardt AR, Fleig SS, Broilo L, Busnello EA. Bipolar I and II disorder residual symptoms: oxcarbazepine and carbamazepine as add-on treatment to lithium in a double-blind, randomized trial. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:94-99. 10.1016/j.pnpbp.2008.10.012, 19007842.
116. T Tohen M, Chengappa KN, Suppes T, Zarate CA, Calabrese JR, Bowden CL, Sachs GS, Kupfer DJ, Baker RW, Risser RC, Keeter EL, Feldman PD, Tollefson GD, Breier A. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry 2002, 59:62-69. 10.1001/archpsyc.59.1.62, 11779284.
117. Houston JP, Ahl J, Meyers AL, Kaiser CJ, Tohen M, Baldessarini RJ. Reduced suicidal ideation in bipolar I disorder mixed-episode patients in a placebo-controlled trial of olanzapine combined with lithium or divalproex. J Clin Psychiatry 2006, 67:1246-1252. 10.4088/JCP.v67n0811, 16965203.
118. Sachs G, Chengappa KN, Suppes T, Mullen JA, Brecher M, Devine NA, Sweitzer DE. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2004, 6:213-223. 10.1111/j.1399-5618.2004.00115.x, 15117400.
119. Yatham LN, Paulsson B, Mullen J, Vagero AM. Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania. J Clin Psychopharmacol 2004, 24:599-606. 10.1097/01.jcp.0000144887.66319.2f, 15538120.
120. Yatham LN, Vieta E, Young AH, Moller HJ, Paulsson B, Vagero M. A double blind, randomized, placebo-controlled trial of quetiapine as an add-on therapy to lithium or divalproex for the treatment of bipolar mania. Int Clin Psychopharmacol 2007, 22:212-220. 10.1097/YIC.0b013e328080ca57, 17519644.
121. Vieta E, T'Joen C, McQuade RD, Carson WH, Marcus RN, Sanchez R, Owen R, Nameche L. Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study. Am J Psychiatry 2008, 165:1316-1325. 10.1176/appi.ajp.2008.07101560, 18381903.
122. Muller-Oerlinghausen B, Retzow A, Henn FA, Giedke H, Walden J. Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomized, double-blind, placebo-controlled, multicenter study. European Valproate Mania Study Group. J Clin Psychopharmacol 2000, 20:195-203. 10.1097/00004714-200004000-00012, 10770458.
123. Weisler R, Dunn J, English P. Adjunctive Ziprasidone for acute bipolar mania: randomized, placebo-controlled trial. 4th International Forum on Mood and Anxiety Disorders 2003, Monte Carlo, Monaco.
124. Roy Chengappa KN, Schwarzman LK, Hulihan JF, Xiang J, Rosenthal NR. Adjunctive topiramate therapy in patients receiving a mood stabilizer for bipolar I disorder: a randomized, placebo-controlled trial. J Clin Psychiatry 2006, 67:1698-1706. 10.4088/JCP.v67n1105, 17196048.
125. Nemeroff CB, Evans DL, Gyulai L, Sachs GS, Bowden CL, Gergel IP, Oakes R, Pitts CD. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry 2001, 158:906-912.
126. Post RM, Altshuler LL, Frye MA, Suppes T, Rush AJ, Keck PE, McElroy SL, Denicoff KD, Leverich GS, Kupka R, Nolen WA. Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers. Bipolar Disord 2001, 3:259-265. 10.1034/j.1399-5618.2001.30505.x, 11912569.
127. Post RM, Altshuler LL, Leverich GS, Frye MA, Nolen WA, Kupka RW, Suppes T, McElroy S, Keck PE, Denicoff KD, Grunze H, Walden J, Kitchen CM, Mintz J. Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br J Psychiatry 2006, 189:124-131. 10.1192/bjp.bp.105.013045, 16880481.
128. Altshuler LL, Post RM, Hellemann G, Leverich GS, Nolen WA, Frye MA, Keck PE, Kupka RW, Grunze H, McElroy SL, Sugar CA, Suppes T. Impact of antidepressant continuation after acute positive or partial treatment response for bipolar depression: a blinded, randomized study. J Clin Psychiatry 2009, 70:450-457. 10.4088/JCP.08m04191, 19358785.
129. Schaffer A, Zuker P, Levitt A. Randomized, double-blind pilot trial comparing lamotrigine versus citalopram for the treatment of bipolar depression. J Affect Disord 2006, 96:95-99. 10.1016/j.jad.2006.05.023, 16820213.
130. Sachs GS, Nierenberg AA, Calabrese JR, Marangell LB, Wisniewski SR, Gyulai L, Friedman ES, Bowden CL, Fossey MD, Ostacher MJ, Ketter TA, Patel J, Hauser P, Rapport D, Martinez JM, Allen MH, Miklowitz DJ, Otto MW, Dennehy EB, Thase ME. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 2007, 356:1711-1722. 10.1056/NEJMoa064135, 17392295.
131. Young LT, Joffe RT, Robb JC, MacQueen GM, Marriott M, Patelis-Siotis I. Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. Am J Psychiatry 2000, 157:124-126. 10.1176/appi.ajp.157.8.1351, 10618026.
132. Tohen M, Chengappa KN, Suppes T, Baker RW, Zarate CA, Bowden CL, Sachs GS, Kupfer DJ, Ghaemi SN, Feldman PD, Risser RC, Evans AR, Calabrese JR. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry 2004, 184:337-345. 10.1192/bjp.184.4.337, 15056579.
133. Gyulai L, Bowden CL, McElroy SL, Calabrese JR, Petty F, Swann AC, Chou JC, Wassef A, Risch CS, Hirschfeld RM, Nemeroff CB, Keck PE, Evans DL, Wozniak PJ. Maintenance efficacy of divalproex in the prevention of bipolar depression. Neuropsychopharmacology 2003, 28:1374-1382. 10.1038/sj.npp.1300190, 12784116.
134. Geddes JR, Goodwin GM, Rendell J, Azorin JM, Cipriani A, Ostacher MJ, Morriss R, Alder N, Juszczak E. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet 2010, 375:385-395. 10.1016/S0140-6736(10)60570-3, 20092882.
135. Fountoulakis KN. The BALANCE trial. Lancet 375:1343-1344. 10.1016/S0140-6736(10)60569-7, 20399972.
136. Rosa AR, Fountoulakis K, Siamouli M, Gonda X, Vieta E. Is anticonvulsant treatment of mania a class effect? Data from randomized clinical trials. CNS Neurosci Ther 2009,
137. Oshima A, Higuchi T, Fujiwara Y, Iida M, Iwanami A, Kanba S, Motohashi N, Uchitomi Y, Yamada K, Yamawaki S. Questionnaire survey on the prescribing practice of Japanese psychiatrists for mood disorders. Psychiatry Clin Neurosci 1999, 53(Suppl):S67-72.
138. Zarate CA, Tohen M, Baraibar G, Kando JC, Mirin J. Prescribing trends of antidepressants in bipolar depression. J Clin Psychiatry 1995, 56:260-264.
139. Ghaemi SN, Hsu DJ, Thase ME, Wisniewski SR, Nierenberg AA, Miyahara S, Sachs G. Pharmacological treatment patterns at study entry for the first 500 STEP-BD participants. Psychiatric Serv 2006, 57:660-665.
140. Levine J, Chengappa KN, Brar JS, Gershon S, Yablonsky E, Stapf D, Kupfer DJ. Psychotropic drug prescription patterns among patients with bipolar I disorder. Bipolar Disord 2000, 2:120-130. 10.1034/j.1399-5618.2000.020205.x, 11252651.
141. Baldessarini RJ, Leahy L, Arcona S, Gause D, Zhang W, Hennen J. Patterns of psychotropic drug prescription for U.S. patients with diagnoses of bipolar disorders. Psychiatric Serv 2007, 58:85-91.
142. Wilting I, Souverein PC, Nolen WA, Egberts AC, Heerdink ER. Changes in outpatient lithium treatment in the Netherlands during 1996-2005. J Affect Disord 2008, 111:94-99. 10.1016/j.jad.2008.01.019, 18342951.
143. Kovacs G. Pharmacotherapeutic trends at the beginning of the millennium in Hungary. Pharmacotherapy for bipolar patients, I. [in Hungarian]. Neuropsychopharmacol Hung 2004, 6:13-18.
144. Lloyd AJ, Harrison CL, Ferrier IN, Young AH. The pharmacological treatment of bipolar affective disorder: practice is improving but could still be better. J Psychopharmacol 2003, 17:230-233. 10.1177/0269881103017002013, 12870572.